CD274 and cancer: Ongoing clinical trials (NCT02734160, NCT02699515, NCT03315871, NCT02423343, and NCT02947165) are investigating the potential of TGF-β targeting antibodies in combination with anti-PD-1/PD-L1 immunotherapy, and may provide promising evidence for the development of combination therapies to enhance the efficacy of existing immunotherapies for cancer treatment.